[Summary text]
Study design: Randomized controlled trial
Study grouping: Crossover
Baseline Characteristics
Overall
Included criteria: All youth had a DSM-IV diagnosisof ADHD, any subtype, and participated in a larger crossovertrial to evaluate comparative efficacy/tolerability and predic-tors of response to MPH and ATX.
Excluded criteria: Exclusionary criteria were:WISC-IV full-scale IQ below 75, non-English speaking parentor child, neurological dysfunction, systemic medical illness,uncorrected sensory impairments, and history of psychosis orbipolar disorder. Other comorbidity was permitted providedADHD was the primary disorder and the comorbid conditiondid not require medication treatment
Pretreatment: Approximately two thirds were male and the majority had either Combined or Inattentive TypeADHD
Intervention Characteristics
Atomoxetin
MPH
ADHD kernesymptomer, lærerbedømt, Change, SD
ADHD kernesymptomer, observatør/kliniker bedømt, Final. SD
ADHD kernesymptomer, observatør/kliniker bedømt, Change SD
Ikke alvorlige bivirkninger-totalt. n
ADHD kernesymptomer, forældre, change, SD
ADHD kernesymptomer, forældre, Final, SD
Frafald pga. bivirkninger, n
Gastrointestinale bivirkninger, n
Søvnforstyrrelse, n
Sponsorship source: This project was funded in part by grants from theNIMH (R01 MH070935, R01 MH70564, DSIR 84-CTM)and the National Center for Research Resources and theNational Center for Advancing Translational Sciences ofthe NIH (UL1TR000067), and through a CanadianInstitutes of Health Research Fellowship to A.-C.V.B.Study medication was provided by Eli Lilly and Co. andOrtho-McNeil-Janssen
Country: USA
Setting: Patients recruited from NYC and chicago
Comments: Clinicaltrials.gov: NCT00183391
Authors name: Anne-Claude V. Bédard
Institution: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY
Email: ac.bedard@mssm.edu
Address: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Box 1230,One Gustave L. Levy Place, New York, NY 10029, USA
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Study design: Randomized controlled trial
Study grouping: Crossover
Included criteria: atients were 6 to 14 years old at study entry. They were diag-nosed with ADHD using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV™) criteria1 as well as severity criteria. Diagnosis was assessed by the investigator’s clinical evaluation and by the administration of several modules of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version structured interview. In addition, patients had an ADHD Rating Scale-IV-Parent Version: Investigator-Administered and Scored (ADHD RS)16 score at least 1.0 standard deviation above normative values for age and sex for either the inattentive or hyperactive/impulsive subscore, or for the combined score. All patients scored at least 80 on the Wechsler Intelligence Scale for Children®-3rdedition.
Excluded criteria: Im-portant exclusion criteria included serious medical illness, a his-tory of symptoms suggestive of a primary sleep disorder—such as obstructive sleep apnea (OSA) (e.g., habitual snoring), periodic limb movement disorder (PLMD, eg, kicking movements during sleep), or insufficient sleep syndrome (e.g., voluntary sleep re-striction resulting in sleep duration habitually significantly short-er than expected age norms)—that could potentially result in a daytime symptom constellation similar to ADHD, and abnormal laboratory values or electrocardiogram (ECG) readings. Patients agreed not to use caffeinated beverages during the duration of the study.
Pretreatment: None detected
Intervention Characteristics
Intervention
Control
Frafald EoT
Abdominal pain
Insomnia
Sponsorship source: This was an industry supported study sponsored by Eli Lilly. The data were analyzed by statisticians at Eli Lilly, including Dr. Sutton, one of the authors. The manuscript was written as a combined effort of all authors. Dr. Sangal has received research support from Eli Lilly, Merck, Organon, Cephalon, and Novartis. Dr. Owens has received research support from Cephalon, Sanofi-Aventis, Johnson Johnson, Sepracor, and Eli Lilly; is a member of the speakers’ bureau for Eli Lilly; is a consultant for Cephalon; and is an advisory board member for Cephalon, Pfizer, and Eli Lilly. Drs. Sutton, Allen, Schuh, and Kelsey are employees of Eli Lilly.
Country: USA
Setting: Two sleep disorders centers in the United States; 1 in a private-practice setting and 1 in a hospital setting
Authors name: Kory J. Schuh
Institution: Clinical Neurophysiology Services, PC, Troy, M
Email: kschuh@lilly.com
Address: Kory J. Schuh, PhD, Eli Lilly and Company, Lilly Corporate Center DC 4135 Indianapolis IN 46285
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Study design: Randomized controlled trial
Study grouping: Parallel group
Abstract
Intervention Characteristics
Intervention 1
Control
Søvnforstyrrelser
Sponsorship source:
Country: USA
Setting:
Comments:
Authors name: M. Stein
Institution:
Email:
Address:
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Study design: Randomized controlled trial
Study grouping: Parallel group
Baseline Characteristics
Intervention 1
Control
Included criteria: Inclusion criteria: patients who aged from six to fourteen and conformed to the ADHD diagnos-tic criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). And the scores ofCGI-ADHD-S of these patients were all higher than 4 points. The informed consent of the children’s guard-ians was obtained.
Excluded criteria: Exclusion criteria: patients who had the psychiatric disorders of mental retardation, autism, schizophrenia, pervasive developmental disorder and so on; patients who didn’t respond to methylphenidate treat-ments previously; and those who had serious physical diseases in heart, lung and other organs
Pretreatment: There was no difference between the two groups at baseline
Intervention Characteristics
Intervention 1
Control
ADHD kernesymptomer, lærerbedømt, Change, SD
ADHD kernesymptomer, observatør/kliniker bedømt, Final. SD
ADHD kernesymptomer, observatør/kliniker bedømt, Change SD
Ikke alvorlige bivirkninger-totalt. n
ADHD kernesymptomer, forældre, change, SD
ADHD kernesymptomer, forældre, Final, SD
Frafald pga. bivirkninger, n
Gastrointestinale bivirkninger, n
Søvnforstyrrelse, n
Sponsorship source:
Country: China
Setting:
Comments:
Authors name: Xia Zhu
Institution: Department of Pediatrics
Email: Tel: +86-0539-2212102
Address: Department of Pediatrics, Linyi Central Hospital, No.17 Jiankang Road, Yishui, Linyi 276400, Shandong, China.
Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence
Judgement Comment: The study is randomized. Not mentioned how it is done
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Only described as 'randomized', no details.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Abstract
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Nothing mentioned
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment
Quote: "Two capsules of OROS MPH or matching placebo and either two or three capsules of ATX (determined by the child’s weight) or matching placebo were administered each morning."
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Only described as 'randomized', no details.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Abstract
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Quote: "The randomized single-blind parallel controlled method was adopted in this research. All children and their patients didn’t know the grouping and types of therapeutic drugs. The"
Judgement Comment: Described that allocation was unknown, but not how concealment was achieved.
Performance bias due to knowledge of the allocated interventions by participants and personnel during the study
Judgement Comment: Nothing mentioned
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Described as double-blind. Both groups get three doses a day. Placebo given as the third dose in the atomoxetine twice a day group.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Abstract
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Quote: "All children and their patients didn’t know the grouping and types of therapeutic drugs."
Detection bias due to knowledge of the allocated interventions by outcome assessors
Quote: "Weekly ratings of ADHD symp- toms and severity of impairment were obtained during a parent interview by blind raters who were trained research assistants, graduate students, or postdoctoral fellows using the ADHD-RS (DuPaul et al., 1998), which was used to track changes in frequency and severity of symptoms during treatment, and aid in clinical decision making."
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Described as double-blind. Both groups get three doses a day. Placebo given as the third dose in the atomoxetine twice a day group
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Abstract
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Quote: "The randomized single-blind parallel controlled method was adopted in this research."
Judgement Comment: Only patients and parents were blinded.
Attrition bias due to amount, nature or handling of incomplete outcome data
Judgement Comment: Dropout has been reported
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Analyzed in total for adverse events: 79 out of 85.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Abstract
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Dropouts have been accounted for
Reporting bias due to selective outcome reporting
Judgement Comment: No. of outcomes mentioned in the study do not match study protocol
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: None detected
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Abstract
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: No other apparent sources of bias
Bias due to problems not covered elsewhere in the table
Judgement Comment: No other apparent sources of bias
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: None detected
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: Abstract
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
See Liu, Q., Zhang, H., Fang, Q. and Qin, L., 2017. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: meta-analysis based on head-to-head trials.
Journal of clinical and experimental neuropsychology, pp.1-12.
Judgement Comment: No other apparent sources of bias